Literature DB >> 30318328

The effect of age on referral to an oncologist and receipt of chemotherapy among small cell lung cancer patients in Ontario, Canada.

Jordan Doherty1, David E Dawe2, Gregory R Pond3, Peter M Ellis4.   

Abstract

OBJECTIVES: Small cell lung cancer (SCLC) represents a significant health burden. There is a lack of information about patterns of referral and treatment for older patients over 70 years of age, in comparison to younger patients with SCLC.
MATERIALS AND METHODS: A population-based retrospective cohort study was undertaken for patients identified from the Ontario Cancer Registry, Canada. All cases of SCLC diagnosed between January 2000 and December 2010 were eligible. Data were extracted on demographic variables, treatment and outcome. Logistic regression analyses were performed as appropriate.
RESULTS: There were 9021 cases of SCLC, with 10% of cases ≥80 years and 32.8% of cases aged 70-79 years and 53% male. Older patients were less likely to be referred to a medical oncologist (OR 0.28 ≥ 80 years, OR 0.60 70-79 years) and less likely to receive chemotherapy (OR 0.19 ≥ 80 years, OR 0.52 70-79 years) compared to younger patients (age < 70). Age, higher comorbidity and prior receipt of home care services were all prognostic of a lower likelihood of referral to a medical oncologist and receipt of chemotherapy. Local health region was also prognostic for referral to and receipt of chemotherapy, indicative of significant regional variation in practice.
CONCLUSIONS: Older patients with SCLC are less likely to be referred for treatment and less likely to receive treatment than younger patients. These data represent a potential gap in knowledge translation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cohort study; Health outcomes; Older patients; Small cell lung cancer

Mesh:

Year:  2018        PMID: 30318328     DOI: 10.1016/j.jgo.2018.10.001

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  3 in total

1.  Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study.

Authors:  Kenji Morimoto; Tadaaki Yamada; Takayuki Takeda; Shinsuke Shiotsu; Koji Date; Taishi Harada; Nobuyo Tamiya; Yusuke Chihara; Osamu Hiranuma; Takahiro Yamada; Hibiki Kanda; Takayuki Nakano; Yoshie Morimoto; Masahiro Iwasaku; Shinsaku Tokuda; Koichi Takayama
Journal:  JTO Clin Res Rep       Date:  2022-06-08

2.  Advanced age is not the decisive factor in chemotherapy of small cell lung cancer: a population-based study.

Authors:  Hanyu Rao; Shunping Zhou; Aihong Mei; Anjie Yao; Shuanshuan Xie
Journal:  Aging (Albany NY)       Date:  2022-06-08       Impact factor: 5.955

3.  Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS Relapse.

Authors:  Peter M Ellis; Anand Swaminath; Gregory R Pond
Journal:  Curr Oncol       Date:  2021-07-20       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.